Frau mit langen schwarzen Haaren, die einen schwarzen Blazer, ein gestreiftes Hemd und eine Perlenkette trägt und mit neutralem Blick in die Kamera schaut - ideal für Profile von Anwälten in Chicago oder von Fachleuten im Bereich des geistigen Eigentumsrechts.

Yogeeta B. Jadhav

Senior Technical Specialist – Chemistry

Yogeeta B. Jadhav

Senior Technical Specialist – Chemistry

Dr. Yogeeta Jadhav thrives on applying her extensive knowledge of chemistry and leveraging over 15 years of patent practice experience to assist clients in protecting their inventions. Her wide-ranging experience includes preparation and prosecution of patent applications; patentability assessment; freedom-to-operate, non-infringement, and patent validity analysis; and due diligence matters spanning a broad spectrum of technologies, including pharmaceuticals, nutraceuticals, chemical compositions and processes, small molecules, vaccines, antibody-drug conjugates, drug formulations, cannabis, food and beverages, personal care products, batteries, pet products, coating and polymers. She is a member of the Firm’s Intellectual Property Department, Health Care & Life Sciences Sector, and Chemical, Biotechnology & Pharmaceutical Practice.

Prior to joining Foley, Yogeeta was a patent scientist at Sandoz India Pvt Ltd, the generic pharmaceuticals division of Novartis. She also worked as a research manager with Lupin Limited, a leading global pharmaceutical company based in Pune, India, where she assisted attorneys with respect to drafting, filing, and prosecuting patent applications; conducting infringement analysis; and evaluating new drug molecules for their patent situation, chemistry, process and technical complexity, and polymorph issues.

After completing her doctoral degree, Yogeeta was a postdoctoral fellow at Monash University in Australia, where she continued her doctoral research focused on the development of a catalytic process for the hydration of aromatic epoxides and phase transfer catalytic reactions in the organic process industry, including agrochemicals, pharmaceuticals, and perfumes, respectively. Her research has resulted in several journal publications and has been presented at national and international conferences.

Präsentationen und Veröffentlichungen

  • “Role of the Omega Phase in the Analysis and Intensification of Solid-Liquid Phase-Transfer-Catalyzed Reactions,” Jadhav, Y.; Yadav, G., Langmuir, 18 (16), 5995–6002, 2002
  • “Synthesis of 2, 4-dichlorophenoxyacetic acid: Novelties of Kinetics of Inverse Phase Transfer Catalysis,” Jadhav, Y.; Yadav, G., J. Mol Catalysis A: Chemical, 184 (1–2), 151–160, 2002
  • “Kinetics and Modeling of Liquid-Liquid Phase Transfer Catalyzed Synthesis of p-chlorophenyl acetonitrile: Role of Co-catalyst in Intensification of Rates and Selectivity,” Jadhav, Y.; Yadav, G., J Molecular Catalysis A: Chemical, 192, 41–52, 2003
  • “Cascade Engineered Phase Transfer Catalysis: A Novel Concept in Green Chemistry,” Jadhav, Y.; Yadav, G., Clean Tech. Environ. Policy, 6(1), 32–42, 2003
  • “Novelties of Solid-Liquid Phase Transfer Catalyzed Synthesis of I-isopropyl-p-chlorophenyl acetonitrile from pchlorophenyl acetonitrile,” Jadhav, Y.; Yadav, G., Organic Process Research & Development, 7(4), 588-598, 2003
  • “Novelties of Kinetics and Mechanism of Liquid-Liquid Phase Transfer Catalyzed Reduction of p-nitroanisole to p-anisidine,” Jadhav, Y.; Yadav, G.; Sengupta, S., Chem. Engg. Science, 55(12), 2681–2689, 2003
  • “Selectively Engineered Phase Transfer Catalysis in the Synthesis of Fine Chemicals: Reactions of p-chloronitrobenzene with sodium sulphide,” Jadhav, Y.; Yadav, G.; Sengupta, J. Molecular Catalysis A: Chemical, 200, 117–129, 2003

Sprachen

  • Hindi (fluent)
  • Marathi (native)
July 10, 2025 Deals and Wins

Foley vertritt Verona Pharma bei $10B-Übernahme durch Merck

Foley & Lardner LLP hat das britische Unternehmen Verona Pharma, ein biopharmazeutisches Unternehmen mit Schwerpunkt auf Atemwegserkrankungen, bei seiner rund 10 Milliarden Dollar schweren Übernahme durch Merck & Co. Inc. (Merck).
June 24, 2024 PharmaPatents

USPTO Publishes Drug Patent and Exclusivity Study Report

The U.S. Patent and Trademark Office in conjunction with the Food and Drug Administration, and in response to January and April 2022 letters from Senator Thom Tillis, has published a report examining the time from approval of a New Drug Application until the first generic launch for 25 drug products, including consideration of patent and regulatory exclusivities.
May 16, 2023 Blogs

Bundesberufungsgericht prüft Patentierbarkeit von sich überschneidenden Bereichen

In der Rechtssache UCB Inc. gegen Actavis Laboratories UT Inc. bestätigte der Federal Circuit das Urteil des Bezirksgerichts zur Ungültigkeit aufgrund von Offensichtlichkeit, hob jedoch die Feststellung zur Vorwegnahme auf.
Curved modern glass building facade with vertical and horizontal lines, featuring the Foley & Lardner LLP logo in the lower right corner—an impressive corporate law office recognized for its lawyers in Chicago.
March 14, 2023 Blogs

USPTO Discusses Duty of Disclosure and Duty of Reasonable Inquiry

On February 23, 2023, the U.S. Patent and Trademark Office held a virtual panel discussion on the duty of disclosure and duty of reasonable inquiry.
January 30, 2023 Blogs

Anhörung des USPTO und der FDA – Stimmen von Patienten- und Patentvertretern

Am 19. Januar 2023 veranstalteten das US-Patent- und Markenamt (USPTO) und die Lebensmittel- und Arzneimittelbehörde (FDA) eine „Anhörung“ mit Schwerpunkt auf den Kooperationsinitiativen von USPTO und FDA, die gemäß der Verordnung von Präsident Biden zur „Förderung des Wettbewerbs in der amerikanischen Wirtschaft“ vorgeschlagen wurden, um „den Zugang zu Medikamenten für amerikanische Familien zu verbessern“.
Eine Nahaufnahme verschiedener Pillen und Kapseln in unterschiedlichen Formen, Größen und Farben – darunter weiß, blau, gelb und beige –, die verstreut liegen, wie man es oft in Fällen sieht, die von Anwaltskanzleien oder Anwälten in Chicago bearbeitet werden.
May 15, 2018 Blogs

Auslegung einer enantiomeren chemischen Struktur

In <EM>Sumitomo Dainippon Pharma Co. V. Emcure Pharm. Ltd</EM>., the Federal Circuit affirmed the district court’s decision that construed a chemical structure as reading on the lurasidone enantiomer that is the active ingredient of Latuda®.